Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCorp RxTSXV:PCRX 36 9-Day RSI is 47.64 as of Jul. 15, 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 698 Healthcare Providers & Services companies, PharmaCorp Rx ranks better than 56.02% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-15), PharmaCorp Rx's 9-Day RSI is 47.64.
The industry rank for PharmaCorp Rx's 9-Day RSI or its related term are showing as below:
TSXV:PCRX's 9-Day RSI is ranked better than 56.02% of 698
companies
in the Healthcare Providers & Services industry
Industry Median: 50.125
vs TSXV:PCRX: 47.64
PharmaCorp Rx (TSXV:PCRX) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
PharmaCorp Rx 9-Day RSI Related Terms
PharmaCorp Rx 9-Day RSI Competitor Comparison
For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCorp Rx 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where PharmaCorp Rx's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx (TSXV:PCRX) has a 9-Day RSI of 47.64 as of Jul. 15, 2026. According to the industry distribution chart, PharmaCorp Rx ranks #307 out of 698 companies in the Healthcare Providers & Services industry, placing it in the top 44%.
Is PharmaCorp Rx's 9-Day RSI too high?
PharmaCorp Rx's current 9-Day RSI is 47.64. The Healthcare Providers & Services industry median 9-Day RSI is 50.13. PharmaCorp Rx's value of 47.64 is 5% below this industry median. Based on the distribution chart, PharmaCorp Rx ranks #307 out of 698 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, PharmaCorp Rx has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's 9-Day RSI compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #307 out of 698 companies for 9-Day RSI. This puts PharmaCorp Rx in the upper half of its industry. The industry median 9-Day RSI is 50.13. PharmaCorp Rx's value of 47.64 is 5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 50.13, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCorp Rx's current 9-Day RSI of 47.64 is 5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 50.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCorp Rx's current 9-Day RSI is 47.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current 9-Day RSI of 47.64. The current 9-Day RSI is 47.64 and 5% below the Healthcare Providers & Services industry median of 50.13. PharmaCorp Rx's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current 9-Day RSI is 47.64 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
36GF Score
Get the complete analysis for TSXV:PCRX
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PCRX has been successfully added to your 
